NCX 470 met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline compared to the standard of care, latanoprost 0.005%.

Included is the supplemental Biologics License Application (sBLA) for EYLEA HD seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week dosing across approved indications.

VivaVision Biotech welcomes renowned ophthalmologist Quan Dong Nguyen to its scientific advisory board with hopes of boosting innovation in ocular disease therapies.

Advances address a need for the growing populace with age-related near vision loss.

Dan Ignaszewski explains how the national advocacy campaign aims to unite patients, researchers, and clinicians to protect NEI’s independence and ensure vision research funding.

Annexin Pharmaceuticals initiates a Phase 2a study for ANXV in diabetic retinopathy to explore new treatment options and improve patient outcomes.

The company previously provided an update in April 2025 stating its intention to lay off approximately 65% of the company after the COAST trial failed to meet its primary end point.

Best disease, or vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and, in some cases, blindness.

Fovea-sparing, multifocal, and bilateral lesions exhibited the fastest growth rates.

Omer Trivizki discusses promising results of VOY-101, a gene therapy for geographic atrophy, highlighting safety and next steps in ongoing research.

jCyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

Extend the summer at EyeCon 2025—where clinical insight meets coastal vibes—September 26 and 27 at the Margaritaville Hollywood Beach Resort in Florida.

The two aim to develop a potential first-in-class melanocortin receptor-targeted treatment for patients with retinal diseases.